Cytokinetics (CYTK) said Monday it has dosed the first participants in a phase 1 clinical study of CK-4015089 as a potential treatment for a specific type of muscular dystrophy and other impaired muscle conditions.
The randomized, double-blind, placebo-controlled study consists of single-dose and multiple-dose ascending cohorts of 10 participants each, said the company
The drug, also called CK-089, increased muscle force and function in animal testing, the company said.
Shares of the company were up 2% in recent Monday premarket activity.
Price: 57.00, Change: +1.16, Percent Change: +2.08
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。